Clinical Trials on Parainfluenza Infection in New Zealand

Total 6786 results

ModernaTX, Inc.

Active, not recruiting

Safety and Immunogenicity of mRNA-1653, a Combined Human Metapneumovirus (hMPV) and Parainfluenza Virus Type 3 (PIV3) Vaccine, in Healthy Adults, and Children 12 to 59 Months of Age With Serologic Evidence of Prior Exposure

Human Metapneumovirus and Human Parainfluenza Infection

United States
AlloVir

Terminated

Study of ALVR106 in Patients With Respiratory Viral Infections After Hematopoietic Cell and Solid Organ Transplant

Influenza Infection | Respiratory Tract Viral Infections | Human Metapneumovirus (hMPV) Infection | Parainfluenza (PIV) Infection | Respiratory Syncytial Viral (RSV) Infection

United States
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Safety and Immunogenicity of a Human Parainfluenza Type 3 (HPIV3) Virus Vaccine in Infants and Children

Parainfluenza Virus 3, Human

United States, Puerto Rico
MedImmune LLC

Completed

Safety and Tolerability Study to Evaluate MEDI-534 in Children 6 to < 24 Months of Age (CP149)

Respiratory Syncytial Virus Infections | Respiratory Viral Infections | Parainfluenza Virus 3, Human

United States
MedImmune LLC

Completed

A Study to Evaluate the Safety, Tolerability, Immunogenicity and Vaccine-like Viral Shedding of MEDI-534, Against Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3), in Healthy 6 to <24 Month-old Children and in 2 Month-old Infants

Healthy

United States, Australia, Spain, Germany, Canada, Finland, South Africa, Brazil, Israel
MedImmune LLC

Completed

Study to Evaluate the Safety of MEDI-534 Vaccine Against Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3) in Healthy Children

Healthy

United States
QIAGEN Gaithersburg, Inc

Completed

Collection and Testing of Respiratory Samples

Respiratory Syncytial Virus Infections | Influenza A | Rhinovirus | Influenza B | QIAGEN ResPlex II Advanced Panel | Infection Due to Human Parainfluenza Virus 1 | Parainfluenza Type 2 | Parainfluenza Type 3 | Parainfluenza Type 4 | Human Metapneumovirus A/B | Coxsackie Virus/Echovirus | Adenovirus Types B/C/E | Coronavirus Subtypes 229E and other conditions

United States
Ansun Biopharma, Inc.

Completed

An Open Label Study to Examine the Effects of DAS181 Administered by Dry Powder Inhaler (DPI) or Nebulized Formulation in Immunocompromised Subjects With Parainfluenza (PIV) Infection (PIV)

Parainfluenza

United States
Enanta Pharmaceuticals, Inc

Terminated

A 2 PART STUDY EVALUATING EDP-721 IN HEALTHY SUBJECTS AND EDP-721 IN COMBINATION WITH EDP-514 IN PATIENTS WITH CHRONIC HEPATITIS B VIRUS INFECTION.

Chronic Hepatitis B Virus Infection

New Zealand
MedImmune LLC

Terminated

A Phase 1/2A Study to Evaluate the Safety, Immunogenicity, and Shedding of MEDI-560 in Infants 1 to < 12 Months of Age

Healthy

United States
Ansun Biopharma, Inc.

Completed

A Phase II, Randomized, Double-blind, Placebo-controlled Study to Examine the Effects of DAS181 in Immunocompromised Subjects With Lower Respiratory Tract Parainfluenza Infection on Supplemental Oxygen (DAS181-2-05)

Parainfluenza

United States
Capital and Coast District Health board
Wellington Southern Community Laboratories; Institute of Environmental Science...

Recruiting

Evaluation of a mNGS Workflow for Infection Diagnosis Using Oxford Nanopore Sequencing.

Bacterial Infections

New Zealand
John Hale

Recruiting

Antiviral Activity of Oral Probiotics

Lower Respiratory Tract Infection | Upper Respiratory Tract Infection

New Zealand
Gilead Sciences

Completed

Study to Evaluate Effect of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination on the Pharmacokinetics of a Representative Hormonal Contraceptive Medication, Norgestimate/Ethinyl Estradiol

HCV Infection

New Zealand
Gilead Sciences

Completed

Sofosbuvir/Velpatasvir Fixed-Dose Combination in HCV-Infected Adults Who Are Undergoing Liver Transplantation

Hepatitis C Virus Infection

New Zealand
Gilead Sciences

Completed

Open-Labeled Study of PSI-7977 and RBV With and Without PEG-IFN in Treatment-Naïve Patients With HCV GT2 or GT3

Chronic Hepatitis C Infection

New Zealand
AmtixBio Co., Ltd.
Novotech (Australia) Pty Limited

Completed

A Study of ATB1651 in Adults With Mild to Moderate Onychomycosis

Onychomycosis

New Zealand
AmtixBio Co., Ltd.

Not yet recruiting

A Study of ATB1651 in Adults With Mild to Moderate Onchomycosis

Onychomycosis

New Zealand
Gilead Sciences

Completed

Efficacy and Safety of Sofosbuvir Containing Regimens for the Treatment of Chronic HCV Infection in Participants With Chronic Genotype 1, 2, 3, or 6 HCV Infection

Chronic Hepatitis C

New Zealand
Valneva Austria GmbH

Completed

VLA2001 Booster in Adult Participants After Priming With mRNA COVID-19 Vaccine and/or Natural SARS-CoV-2 Infection

SARS-CoV-2 Infection

New Zealand, Netherlands
Ansun Biopharma, Inc.

Recruiting

Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study

COVID-19 | Lower Respiratory Tract Infection | Immunocompromised | Parainfluenza

United States, Australia, China, Denmark, France, Hong Kong, Korea, Republic of, Taiwan
Syneos Health
F-star Therapeutics, Inc.

Completed

A Multiple Ascending Dose Phase I Study of SB 9200 in Treatment Naïve Adults With Chronic Hepatitis C Infection

Hepatitis C Infection

Australia, New Zealand
Enanta Pharmaceuticals, Inc
Novotech (Australia) Pty Limited

Completed

EDP-494-001: A Study of EDP-494 in Healthy Subjects and Hepatitis C Patients

Hepatitis C

New Zealand
Ellume Pty Ltd

Withdrawn

Performance of Ellume·Lab Group A Strep Test Versus Culture for the Rapid Detection of Group A Streptococcus in Participants With Acute Pharyngitis

Group A Streptococcal Infection

New Zealand
University of Auckland, New Zealand

Completed

The Effect of Extended Yellow Fever Vaccine Information on Symptom Reports Following Vaccination

Vaccination

New Zealand
Akesobio Australia Pty Ltd

Completed

A Study of AK119 (Anti-CD73 Antibody), a Treatment for COVID-19, in Healthy Subjects

Coronavirus Disease 2019 (COVID-19)

New Zealand
Qilu Pharmaceutical Co., Ltd.

Unknown

A Study to Investigate the Safety, Efficacy and Pharmacokinetic Profile of Multiple Doses of QL-007 in Chronic Hepatitis B Patients

Chronic Hepatitis b

New Zealand
Hoffmann-La Roche

Completed

A Study on Safety, Tolerability and Pharmacokinetics of RO5303253 in Healthy Volunteers and Patients With Chronic Hepatitis C Genotype 1

Hepatitis C, Chronic, Healthy Volunteer

New Zealand
Arrow Therapeutics

Completed

Antiviral Activity of AZD7295 in HCV Carriers

Hepatitis C

New Zealand
Vertex Pharmaceuticals Incorporated

Completed

Drug-Drug Interaction Study of VCH-222 and Telaprevir in Healthy Subjects

Hepatitis C

New Zealand
Alios Biopharma Inc.

Completed

A Study of AL-034 to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses in Healthy Participants

Hepatitis B

New Zealand
Murdoch Childrens Research Institute

Recruiting

BonE and Joint Infections - Simplifying Treatment in Children Trial (BEST)

Osteomyelitis | Septic Arthritis | Bone Infection | Bone and Joint Infection

New Zealand, Australia
Vaxart

Completed

Assessment of an Oral Influenza B Vaccine Tablet (VXA-BYW.10) Following Single Dose Administration in Healthy Adults

Seasonal Influenza B

New Zealand
Assembly Biosciences

Not yet recruiting

A Study to Assess the Safety, Pharmacokinetics, and Antiviral Activity of ABI-5366 in Healthy Participants and Participants Seropositive for HSV-2 With Recurrent Genital Herpes

Recurrent Genital Herpes Simplex Type 2

New Zealand
Gilead Sciences

Completed

Efficacy and Safety of Tenofovir Alafenamide (TAF) Versus Tenofovir Disoproxil Fumarate (TDF)-Containing Regimens in Participants With Chronic Hepatitis B Virus (HBV) Infection and Stage 2 or Greater Chronic Kidney Disease Who Have Received a Liver Transplant

Chronic Hepatitis B

New Zealand
Soroka University Medical Center
Eiger BioPharmaceuticals

Active, not recruiting

Once Daily Dosing of Lonafarnib Co-administered With Ritonavir for Treatment of Chronic Hepatitis D Virus Infection (LOWR6)

Hepatitis D, Chronic

Israel, New Zealand, Turkey
Assembly Biosciences

Completed

A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABI-H3733 in Healthy Adults

Chronic Hepatitis B

New Zealand
Novartis Pharmaceuticals

Terminated

A Two Week Dosing Study to Determine the Safety and Antiviral Activity of LCQ908 in Hepatitis C Patients

Hepatitis C

New Zealand
Janssen Research & Development, LLC

Terminated

A Single and Multiple Ascending Dose Study of JNJ-64457744

Healthy | Hepatitis B, Chronic

New Zealand
Jiangsu Rec-Biotechnology Co., Ltd.
Iqvia Pty Ltd

Completed

Safety, Reactogenicity and Immunogenicity Study of ReCOV

Covid19

New Zealand
Restorbio Inc.

Completed

A Phase 3 Study to Determine if RTB101 Prevents Clinically Symptomatic Respiratory Illness in the Elderly

Respiratory Tract Infections

New Zealand
Arrowhead Pharmaceuticals

Terminated

A Study of ARC-521 Injection in Normal Adult Volunteers and Patients With Chronic Hepatitis B (CHB)

Hepatitis B

New Zealand
Eiger BioPharmaceuticals

Completed

A Study to Evaluate Pegylated Interferon Lambda Monotherapy in Patients With Chronic Hepatitis Delta Virus Infection (LIMT)

Hepatitis D, Chronic

Israel, New Zealand, Pakistan
Assembly Biosciences

Completed

A Study in Healthy Volunteers and Patients With Chronic Hepatitis B

Chronic Hepatitis B

New Zealand
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity of Two Dosages of Inactivated, Split-Virion Influenza Vaccine Given by an Alternate Route in the Elderly

Influenza | Orthomyxoviridae Infection | Myxovirus Infection

Australia, New Zealand
Alios Biopharma Inc.

Terminated

Study of the Relative Oral Bioavailability of AL-3778 Tablets and Drug Interaction With Entecavir or Tenofovir Disoproxil Fumarate in Healthy Volunteers

Hepatitis B | Chronic Hepatitis B | Viral Hepatitis B

New Zealand
Antipodean Pharmaceuticals, Inc.

Completed

Trial of MitoQ for Raised Liver Enzymes Due to Hepatitis C

Chronic Hepatitis C

New Zealand
Vertex Pharmaceuticals Incorporated

Completed

A Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of VX-135 and Daclatasvir in Subjects With Genotype 1 Chronic Hepatitis C Chronic Hepatitis C

Hepatitis C | Chronic Hepatitis C | HCV | CHC

New Zealand
Murdoch Childrens Research Institute
Royal Children's Hospital

Recruiting

Single Dose Intravenous Antibiotics for Complicated Urinary Tract Infections in Children (CHOICE UTI)

Infection | Pediatric Infectious Disease | Complicated Urinary Tract Infection

Australia, New Zealand
Gilead Sciences

Completed

Efficacy and Safety of Oral Regimens for the Treatment of Chronic HCV Infection (LEPTON)

Chronic Hepatitis C

New Zealand

3

Subscribe